[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30. doi: 10.3322/caac.21387
[2] Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers: a heterogeneous set of diseases[J]. Nat Rev Cancer, 2014, 14(8): 535-546. doi: 10.1038/nrc3775
[3] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008, 58(2): 71-96. doi: 10.3322/ca.2007.0010
[4] Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013[J]. JAMA Oncol, 2015, 1(4): 505-527. doi: 10.1001/jamaoncol.2015.0735
[5] Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676): 1497-1500. doi: 10.1126/science.1099314
[6] Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350(21): 2129-2139. doi: 10.1056/NEJMoa040938
[7] Felip E, Gridelli C, Baas P, et al. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010[J]. Ann Oncol, 2011, 22(7): 1507-1519. doi: 10.1093/annonc/mdr150
[8] Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing[J]. Genome Res, 2012, 22(3): 436-445. doi: 10.1101/gr.133645.111
[9] Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations[J]. Clin Cancer Res, 2012, 18(4): 1167-1176. doi: 10.1158/1078-0432.ccr-11-2109
[10] Li C, Gao Z, Li F, et al. Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma[J]. Sci Rep, 2015, 5: 14237. doi: 10.1038/srep14237
[11] Kim Y, Hammerman PS, Kim J, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients[J]. J Clin Oncol, 2014, 32(2): 121-128. doi: 10.1200/jco.2013.50.8556
[12] Comprehensive genomic characterization of squamous cell lung cancers[J]. Nature, 2012, 489(7417): 519-525. doi: 10.1038/nature11404
[13] Takahashi T, Sonobe M, Menju T, et al. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer[J]. J Surg Oncol, 2010, 101(6): 500-506. doi: 10.1002/jso.21520
[14] Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2[J]. Mol Cell Biol, 2004, 24(16): 7130-7139. doi: 10.1128/mcb.24.16.7130-7139.2004
[15] Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context[J]. Nat Rev Cancer, 2012, 12(8): 564-571. doi: 10.1038/nrc3278
[16] Rotblat B, Melino G, Knight RA. NRF2 and p53: Januses in cancer?[J]. Oncotarget, 2012, 3(11): 1272-1283. doi: 10.18632/oncotarget.754
[17] Shibata T, Ohta T, Tong KI, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy[J]. Proc Natl Acad Sci U S A, 2008, 105(36): 13568-13573. doi: 10.1073/pnas.0806268105
[18] Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism[J]. Trends Biochem Sci, 2014, 39(4): 199-218. doi: 10.1016/j.tibs.2014.02.002
[19] Singh A, Boldin-Adamsky S, Thimmulappa RK, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy[J]. Cancer Res, 2008, 68(19): 7975-7984. doi: 10.1158/0008-5472.can-08-1401
[20] Romero R, Sayin VI, Davidson SM, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis[J]. Nat Med, 2017, 23(11): 1362-1368. doi: 10.1038/nm.4407
[21] Singh A, Bodas M, Wakabayashi N, et al. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance[J]. Antioxid Redox Signal, 2010, 13(11): 1627-1637. doi: 10.1089/ars.2010.3219
[22] Jeong Y, Hoang NT, Lovejoy A, et al. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance[J]. Cancer Discov, 2017, 7(1): 86-101. doi: 10.1158/2159-8290.cd-16-0127
[23] Adams J, Kelso R, Cooley L. The kelch repeat superfamily of proteins: propellers of cell function[J]. Trends Cell Biol, 2000, 10(1): 17-24. doi:
[24] Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain[J]. Genes Dev, 1999, 13(1): 76-86. doi:
[25] Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers[J]. Proc Natl Acad Sci U S A, 2004, 101(7): 2040-2045. doi: 10.1073/pnas.0307301101
[26] Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy[J]. Nat Rev Drug Discov, 2013, 12(12): 931-947. doi: 10.1038/nrd4002
[27] Singh A, Venkannagari S, Oh KH, et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors[J]. ACS Chem Biol, 2016, 11(11): 3214-3225. doi: 10.1021/acschembio.6b00651
[28] Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive Characterization of Cancer Driver Genes and Mutations[J]. Cell, 2018, 173(2): 371-385.e318. doi: 10.1016/j.cell.2018.02.060
[29] Hayes JD, McMahon M, Chowdhry S, et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway[J]. Antioxid Redox Signal, 2010, 13(11): 1713-1748. doi: 10.1089/ars.2010.3221
[30] McCarthy N. Tumorigenesis: oncogene detox programme[J]. Nat Rev Cancer, 2011, 11(9): 622-623. doi: 10.1038/nrc3119
[31] Hu R, Saw CL, Yu R, et al. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory[J]. Antioxid Redox Signal, 2010, 13(11): 1679-1698. doi: 10.1089/ars.2010.3276
[32] Perera RM, Bardeesy N. Cancer: when antioxidants are bad[J]. Nature, 2011, 475(7354): 43-44. doi: 10.1038/475043a
[33] Lignitto L, LeBoeuf SE, Homer H, et al. Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1[J]. Cell, 2019, 178(2): 316-329.e318. doi: 10.1016/j.cell.2019.06.003
[34] Best SA, De Souza DP, Kersbergen A, et al. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment[J]. Cell Metab, 2018, 27(4): 935-943.e934. doi: 10.1016/j.cmet.2018.02.006
[35] Fukazawa T, Guo M, Ishida N, et al. SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma[J]. Sci Rep, 2016, 6: 20113. doi: 10.1038/srep20113
[36] Perez-Moreno P, Brambilla E, Thomas R, et al. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities[J]. Clin Cancer Res, 2012, 18(9): 2443-2451. doi: 10.1158/1078-0432.ccr-11-2370
[37] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373(2): 123-135. doi: 10.1056/NEJMoa1504627
[38] LeBoeuf SE, Wu WL, Karakousi TR, et al. Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids[J]. Cell metabolism, 2020, 31(2): 339-350.e334. doi: 10.1016/j.cmet.2019.11.012
[39] Ren D, Villeneuve NF, Jiang T, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism[J]. Proc Natl Acad Sci U S A, 2011, 108(4): 1433-1438. doi: 10.1073/pnas.1014275108
[40] Choi EJ, Jung BJ, Lee SH, et al. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer[J]. Oncogene, 2017, 36(37): 5285-5295. doi: 10.1038/onc.2017.153
[41] Lu MC, Ji JA, Jiang ZY, et al. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update[J]. Med Res Rev, 2016, 36(5): 924-963. doi: 10.1002/med.21396
[42] Menegon S, Columbano A, Giordano S. The Dual Roles of NRF2 in Cancer[J]. Trends Mol Med, 2016, 22(7): 578-593. doi: 10.1016/j.molmed.2016.05.002